PANews reported on August 12th that Ethereum co-founder Vitalik Buterin published an article today, arguing that the development of cutting-edge technologies like life extension and gene editing, if controlled byPANews reported on August 12th that Ethereum co-founder Vitalik Buterin published an article today, arguing that the development of cutting-edge technologies like life extension and gene editing, if controlled by

Vitalik: Open source technology has the potential to alleviate the power inequality exacerbated by technology

2025/08/12 19:32
1 min read

PANews reported on August 12th that Ethereum co-founder Vitalik Buterin published an article today, arguing that the development of cutting-edge technologies like life extension and gene editing, if controlled by a small number of companies or countries, could exacerbate global wealth disparity and the concentration of power. The author advocated for the mainstream view that "developing technology exclusively under open source conditions" should become mainstream. Open source not only increases technological accessibility but also reduces vendor lock-in, enhances security and transparency, and empowers global users to produce and verify. The article emphasizes that open source is an effective path to preventing technological abuse and power imbalances, and recommends prioritizing the open source model when promoting new technologies.

Market Opportunity
Edge Logo
Edge Price(EDGE)
$0.09897
$0.09897$0.09897
-5.81%
USD
Edge (EDGE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.